Amrad Corporation Limited

Meredith Jane Layton

Donald Metcalf

Richard John Simpson

Nicos Anthony Nicola

Nicholas Martin Gough

Nicos Antony Nicola

Catherine Mary Owczarek

The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro to a greater extent when compared to its ability to inhibit LIF from said first mammalian species.

Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)

The present invention relates generally to molecules carrying one or more binding determinants for &agr;-chain of human Leukaemia Inhibitory Factor binding receptor and to genetic sequences encoding same. More particularly, the present invention contemplates a molecule which is non-naturally occurring and which comprises a carrier portion and an active portion and wherein the active portion comprises amino acid residues or chemical equivalents thereof which constitute a binding determinant for the &agr; chain of the human leukaemia inhibitory factor (hLIF) binding receptor.

Receptor-binding determinant from leukaemia inhibitory factor

Growing community of inventors

Tecoma, Australia

Meredith Jane Layton